title: Infliximab-induced psoriasis during therapy for Crohn's disease.
abstract: Although therapy with tumor necrosis factor-alpha inhibitors (anti-TNF) provides beneficial effects in different immune inflammatory disorders, paradoxical cases of anti-TNF-induced psoriasis have increasingly been reported, mostly in the setting of rheumatologic diseases. To date, less than 50 cases of infliximab-induced psoriasis in inflammatory bowel disease patients have been described. The present report was aimed at describing two new cases of infliximab-induced psoriasis during therapy for Crohn's disease and at carrying out a review on this intriguing phenomenon.
authors.affiliation: Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. flavio@steinwurz.net
authors.forename: Flavio
authors.initials: F
authors.lastname: Steinwurz
authors.forename: Rafael
authors.initials: R
authors.lastname: Denadai
authors.forename: Rogério
authors.initials: R
authors.lastname: Saad-Hossne
authors.forename: Maria Luiza
authors.initials: ML
authors.lastname: Queiroz
authors.forename: Fábio Vieira
authors.initials: FV
authors.lastname: Teixeira
authors.forename: Ricardo
authors.initials: R
authors.lastname: Romiti
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab